The Effect of Informative Letters on the Prescription and Receipt of Seroquel
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02467933|
Recruitment Status : Unknown
Verified March 2016 by Abdul Latif Jameel Poverty Action Lab.
Recruitment status was: Active, not recruiting
First Posted : June 10, 2015
Last Update Posted : March 8, 2016
|Condition or disease||Intervention/treatment||Phase|
|Economics Fraud Delivery of Health Care Health Expenditures Centers for Medicare and Medicaid Services (U.S.)||Other: Placebo letter Other: Initial Informative letter Other: Followup Informative Letter||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5055 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||The Effect of Informative Letters on the Prescription and Receipt of Seroquel|
|Study Start Date :||April 2015|
|Estimated Primary Completion Date :||July 2017|
|Estimated Study Completion Date :||December 2017|
Placebo Comparator: Placebo
The placebo arm receives a placebo letter unrelated to Seroquel
Other: Placebo letter
The placebo letter describes a new rule in Medicare that requires prescribers to enroll in Medicare
Experimental: Informative Letter
The interventional arm prescribers receive an initial informative letter (called a comparative billing report or peer activity report) followed by 2 followup informative letters at approximately 3 month intervals.
Other: Initial Informative letter
The intervention is a letter that describes the Seroquel prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.Other: Followup Informative Letter
The followup informative letter is identical to the initial informative letter except it provides an update on more recent prescribing rather than a description of earlier prescribing.
- 30-day equivalent prescribing of Seroquel treatments [ Time Frame: 9 months ]The prescribing of Seroquel over the 9 months following the initial sending of the letters. Prescribing is defined as the total "days supply" of Seroquel attributed to the prescriber, expressed in "30-day equivalents" i.e. divided by 30.
- 30-day equivalent prescribing of Seroquel treatments [ Time Frame: 3 months ]
- 30-day equivalent prescribing of Seroquel treatments [ Time Frame: 6 months ]
- 30-day equivalent prescribing of Seroquel treatments [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02467933
|Principal Investigator:||Adam Sacarny, PhD||Columbia University|